{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:03:54Z","timestamp":1794056634950,"version":"4.8.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.metabol.2025.156190","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:01:36Z","timestamp":1741694496000},"page":"156190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease: A sexually dimorphic disease and breast and gynecological cancer"],"prefix":"10.1016","volume":"167","author":[{"given":"Xinrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156190_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global burden of disease study","author":"Tan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2025.156190_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.metabol.2025.156190_bb0020","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2025.156190_bb0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.08.013","article-title":"Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: biological sex matters","volume":"80","author":"Ji","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156190_bb0040","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.tips.2024.05.004","article-title":"Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment","volume":"45","author":"Booijink","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.metabol.2025.156190_bb0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.metabol.2025.156190_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/189384","article-title":"Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis","volume":"2014","author":"Bhandari","year":"2014","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0055","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/GME.0b013e31828ce95d","article-title":"Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis","volume":"20","author":"Esposito","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.metabol.2025.156190_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-020-0199-6","article-title":"Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.metabol.2025.156190_bb0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0070","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156190_bb0075","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32758","article-title":"Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH","volume":"77","author":"Tan","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156190_bb0080","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk","volume":"34","author":"Ballestri","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.metabol.2025.156190_bb0085","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0090","article-title":"Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling","volume":"11","author":"Della","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2025.156190_bb0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00026.2006","article-title":"Estrogen receptors: how do they signal and what are their targets","volume":"87","author":"Heldring","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2025.156190_bb0100","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.metabol.2025.156190_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of estrogens in the regulation of liver lipid metabolism","volume":"1043","author":"Palmisano","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.metabol.2025.156190_bb0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","article-title":"AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance","volume":"66","author":"Garcia","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.metabol.2025.156190_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2025.156190_bb0120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0125","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.4049\/jimmunol.0901737","article-title":"Estrogen regulates transcription factors STAT-1 and NF-kappaB to promote inducible nitric oxide synthase and inflammatory responses","volume":"183","author":"Dai","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.metabol.2025.156190_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-\u03baB in the liver--linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0135","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/JOE-19-0321","article-title":"Effects of ER\u03b2 and ER\u03b1 on OVX-induced changes in adiposity and insulin resistance","volume":"245","author":"Zidon","year":"2020","journal-title":"J Endocrinol"},{"key":"10.1016\/j.metabol.2025.156190_bb0145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/db11-1718","article-title":"Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance","volume":"62","author":"Zhu","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2025.156190_bb0150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1665-2681(19)31616-3","article-title":"Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens","volume":"9","author":"Gutierrez-Grobe","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejogrb.2015.04.017","article-title":"Menopausal stages and non-alcoholic fatty liver disease in middle-aged women","volume":"190","author":"Ryu","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.metabol.2025.156190_bb0160","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10654-019-00526-1","article-title":"Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the clinical practice research datalink","volume":"34","author":"Florio","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.metabol.2025.156190_bb0165","doi-asserted-by":"crossref","first-page":"15461","DOI":"10.1038\/s41598-023-42788-6","article-title":"Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156190_bb0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/oby.21033","article-title":"The role of androgens in metabolism, obesity, and diabetes in males and females","volume":"23","author":"Navarro","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2025.156190_bb0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2025.156190_bb0180","first-page":"12","article-title":"Non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression","author":"Manzano-Nunez","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0185","article-title":"Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men","volume":"19","author":"Sarkar","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0190","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1210\/en.2015-1713","article-title":"Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice","volume":"157","author":"Dubois","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2025.156190_bb0195","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac127","article-title":"Androgen-mediated perturbation of the hepatic circadian system through epigenetic modulation promotes NAFLD in PCOS mice","volume":"163","author":"Roy","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2025.156190_bb0200","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40618-017-0762-3","article-title":"Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index","volume":"41","author":"Condorelli","year":"2018","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.metabol.2025.156190_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database","volume":"15","author":"Kumarendran","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156190_bb0215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/jnci\/djab102","article-title":"The role of Mendelian randomization studies in deciphering the effect of obesity on cancer","volume":"114","author":"Fang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.metabol.2025.156190_bb0220","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1055-9965.EPI-16-0147","article-title":"Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer","volume":"25","author":"Painter","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.metabol.2025.156190_bb0225","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ije\/dyw158","article-title":"Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study","volume":"45","author":"Dixon","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.metabol.2025.156190_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002105","article-title":"Genetically predicted body mass index and breast cancer risk: Mendelian randomization analyses of data from 145,000 women of European descent","volume":"13","author":"Guo","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0235","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ije\/dyw129","article-title":"Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer","volume":"45","author":"Gao","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.metabol.2025.156190_bb0240","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/db20-0084","article-title":"Is type 2 diabetes causally associated with cancer risk? Evidence from a two-sample Mendelian randomization study","volume":"69","author":"Yuan","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2025.156190_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218917","article-title":"Post genome-wide gene-environment interaction study: the effect of genetically driven insulin resistance on breast cancer risk using Mendelian randomization","volume":"14","author":"Jung","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2025.156190_bb0250","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/hep4.1751","article-title":"Association of genetic risk score with NAFLD in an ethnically diverse cohort","volume":"5","author":"Wang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2025.156190_bb0255","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21846","article-title":"Obesity and early-onset breast cancer and specific molecular subtype diagnosis in black and white women: NIMHD social epigenomics program","volume":"7","author":"Sudan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2025.156190_bb0265","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s10552-023-01716-9","article-title":"Racial and ethnic differences in tumor characteristics among endometrial cancer patients in an equal-access healthcare population","volume":"34","author":"Desmond","year":"2023","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.metabol.2025.156190_bb0270","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2022.11.015","article-title":"Racial and ethnic differences in type II endometrial cancer mortality outcomes: the contribution of sociodemographic, clinicopathologic, and treatment factors","volume":"168","author":"Karia","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.metabol.2025.156190_bb0275","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-15-0293","article-title":"Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status","volume":"24","author":"Chen","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.metabol.2025.156190_bb0280","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.metabol.2025.156190_bb0285","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0290","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14276","article-title":"Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies","volume":"54","author":"Zhou","year":"2024","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.metabol.2025.156190_bb0295","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/apt.18286","article-title":"Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: a nationwide cohort study","volume":"60","author":"Park","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2025.156190_bb0300","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/hbsn-21-546","article-title":"Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China","volume":"12","author":"Yuan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.metabol.2025.156190_bb0305","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1136\/gutjnl-2022-328887","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer","volume":"72","author":"Roderburg","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2025.156190_bb0310","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2025.156190_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156190_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2020.02.004","article-title":"Association between fatty liver index and risk of breast cancer: a nationwide population-based study","volume":"20","author":"Park","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0325","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.dld.2018.12.024","article-title":"Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women","volume":"51","author":"Kwak","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2025.156190_bb0330","article-title":"Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery","volume":"98","author":"Lee","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2025.156190_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.985858","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2025.156190_bb0340","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1038\/s41598-023-44243-y","article-title":"AST\/ALT-to-platelet ratio (AARPRI) predicts gynaecological cancers: a 8-years follow-up study in 653 women","volume":"13","author":"Crudele","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156190_bb0345","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.3390\/curroncol30040287","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with cervical stromal involvement in endometrial cancer patients: a cross-sectional study in South China","volume":"30","author":"Lin","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.metabol.2025.156190_bb0350","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0355","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","author":"Kim","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0360","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002080","article-title":"Nonalcoholic cirrhosis increased risk of digestive tract malignancies: a population-based cohort study","volume":"94","author":"Sun","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2025.156190_bb0365","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nm.4350","article-title":"Insulin action and resistance in obesity and type 2 diabetes","volume":"23","author":"Czech","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2025.156190_bb0375","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.2337\/dc08-s264","article-title":"Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?","volume":"31","author":"Shanik","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2025.156190_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156014","article-title":"Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers","volume":"160","author":"Mantovani","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156190_bb0385","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/789174","article-title":"Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms","volume":"2012","author":"Arcidiacono","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.metabol.2025.156190_bb0390","article-title":"A systematic review: does insulin resistance affect the risk and survival outcome of breast cancer in women?","volume":"14","author":"Srinivasan","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.metabol.2025.156190_bb0395","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1210\/endrev\/bnad015","article-title":"Update on adipose tissue and cancer","volume":"44","author":"Brown","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2025.156190_bb0400","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbabio.2010.11.004","article-title":"Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach","volume":"1807","author":"Prieto-Hontoria","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2025.156190_bb0405","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/er.2011-1015","article-title":"The role of adiponectin in cancer: a review of current evidence","volume":"33","author":"Dalamaga","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2025.156190_bb0410","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.2174\/092986712803833137","article-title":"Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer","volume":"19","author":"Perrier","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.metabol.2025.156190_bb0415","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41575-018-0038-1","article-title":"Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions","volume":"15","author":"Murphy","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0420","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12916-022-02319-y","article-title":"Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort","volume":"20","author":"Cairat","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2010.07.007","article-title":"Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects","volume":"119","author":"Ashizawa","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.metabol.2025.156190_bb0430","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1210\/jc.2002-021209","article-title":"Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece","volume":"88","author":"Petridou","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2025.156190_bb0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.metabol.2025.156190_bb0440","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.metabol.2025.156190_bb0445","doi-asserted-by":"crossref","first-page":"50","DOI":"10.12938\/bmfh.2020-046","article-title":"Correlation of gut Firmicutes\/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease","volume":"40","author":"Jasirwan","year":"2021","journal-title":"Biosci Microbiota Food Health"},{"key":"10.1016\/j.metabol.2025.156190_bb0450","first-page":"8","article-title":"Gut microbial metabolites in MASLD: implications of mitochondrial dysfunction in the pathogenesis and treatment","author":"Zhang","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2025.156190_bb0455","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0460","first-page":"21","article-title":"The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship","author":"Sampsell","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2025.156190_bb0465","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbabio.2018.04.002","article-title":"Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness","volume":"1859","author":"Mik\u00f3","year":"2018","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10.1016\/j.metabol.2025.156190_bb0470","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41522-024-00577-7","article-title":"Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value","volume":"10","author":"Wu","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.metabol.2025.156190_bb0475","article-title":"Role of gut microbiota dysbiosis in breast cancer and novel approaches in prevention, diagnosis, and treatment","volume":"13","author":"Ruo","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.metabol.2025.156190_bb0480","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2025.156190_bb0485","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10555-006-9000-8","article-title":"The paradox of pro-inflammatory cytokines in cancer","volume":"25","author":"Dinarello","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.metabol.2025.156190_bb0490","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.metabol.2025.156190_bb0495","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbrc.2015.10.133","article-title":"Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer","volume":"472","author":"Suman","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2025.156190_bb0500","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1020304003704","article-title":"Tumor-associated macrophages in breast cancer","volume":"7","author":"Leek","year":"2002","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.metabol.2025.156190_bb0505","first-page":"9","article-title":"The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer","author":"Nowak","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2025.156190_bb0510","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2025.156190_bb0515","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/CEJ.0b013e32835b3813","article-title":"Case-control study of inflammatory markers and the risk of endometrial cancer","volume":"22","author":"Friedenreich","year":"2013","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.metabol.2025.156190_bb0520","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1677\/ERC-10-0053","article-title":"Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study","volume":"17","author":"Dossus","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101138","article-title":"Hepatokines and metabolism: deciphering communication from the liver","volume":"44","author":"Jensen-Cody","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2025.156190_bb0530","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2025.156190_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312918","article-title":"The role of fetuin-A in tumor cell growth, prognosis, and dissemination","volume":"25","author":"Odiase","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2025.156190_bb0540","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5937\/jomb0-37386","article-title":"Serum fetuin-A and RANKL levels in patients with early stage breast cancer","volume":"42","author":"Afsar","year":"2023","journal-title":"J Med Biochem"},{"key":"10.1016\/j.metabol.2025.156190_bb0545","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12964-024-02003-z","article-title":"Role of the serum levels of the inter-organs messenger fibroblast growth factor 21 (FGF21) in the diagnosis and prognosis of breast cancer patients","volume":"23","author":"Ranuncolo","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.metabol.2025.156190_bb0550","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/CBM-161507","article-title":"The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy","volume":"18","author":"Akyol","year":"2017","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.metabol.2025.156190_bb0555","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3892\/ol.2020.11768","article-title":"ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.metabol.2025.156190_bb0560","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.18632\/oncotarget.27553","article-title":"Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases risk of brain metastases in women with breast cancer","volume":"11","author":"Dao","year":"2020","journal-title":"Oncotarget"},{"issue":"Pt 6","key":"10.1016\/j.metabol.2025.156190_bb0565","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/000456329002700603","article-title":"Sex hormone binding globulin: origin, function and clinical significance","volume":"27","author":"Selby","year":"1990","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.metabol.2025.156190_bb0570","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","article-title":"Sex hormone-binding globulin and risk of type 2 diabetes in women and men","volume":"361","author":"Ding","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156190_bb0575","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1677\/joe.0.1750113","article-title":"Sex hormone-binding globulin is synthesized in target cells","volume":"175","author":"Kahn","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.metabol.2025.156190_bb0580","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0034-1395606","article-title":"Sex hormone binding globulin and risk of breast cancer in postmenopausal women: a meta-analysis of prospective studies","volume":"47","author":"He","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metabol.2025.156190_bb0585","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/s41416-021-01518-3","article-title":"Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses","volume":"125","author":"Mullee","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0590","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ijc.11529","article-title":"Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women","volume":"108","author":"Lukanova","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0595","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-28032013000200032","article-title":"Nonalcoholic fatty liver disease in menopausal women","volume":"50","author":"Florentino","year":"2013","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.metabol.2025.156190_bb0600","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2265.2006.02543.x","article-title":"Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial","volume":"65","author":"McKenzie","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.metabol.2025.156190_bb0605","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3748\/wjg.v18.i3.237","article-title":"Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women","volume":"18","author":"Hamaguchi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2025.156190_bb0610","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.26761","article-title":"Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156190_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.07.034","article-title":"Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis","volume":"15","author":"Yang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0620","article-title":"Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population","volume":"19","author":"Wang","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156190_bb0625","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000055319","article-title":"Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates","volume":"60","author":"Beckmann","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.metabol.2025.156190_bb0630","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/bcr1035","article-title":"Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence","volume":"7","author":"Col","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.metabol.2025.156190_bb0635","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2025.156190_bb0640","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0645","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2025.156190_bb0650","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.metabol.2025.156190_bb0655","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0660","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13697137.2020.1826426","article-title":"Hormone replacement therapy and cervical cancer: a systematic review of the literature","volume":"24","author":"Vargiu","year":"2021","journal-title":"Climacteric"},{"key":"10.1016\/j.metabol.2025.156190_bb0665","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.180.1.1800129","article-title":"Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy","volume":"180","author":"Nishino","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.metabol.2025.156190_bb0670","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.maturitas.2008.04.009","article-title":"Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women","volume":"60","author":"Lee","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.metabol.2025.156190_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189911","article-title":"Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits liver health","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2025.156190_bb0680","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1078-0432.CCR-12-3771","article-title":"Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease","volume":"19","author":"Wardell","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2025.156190_bb0685","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00198-010-1440-x","article-title":"Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene\/conjugated estrogens (BZA\/CE)","volume":"22","author":"Lindsay","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2025.156190_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.6.1.1","article-title":"Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?","volume":"6","author":"Osman","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.metabol.2025.156190_bb0695","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.metabol.2025.156190_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088525","article-title":"Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options","volume":"9","author":"Gasparini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2025.156190_bb0710","doi-asserted-by":"crossref","first-page":"585","DOI":"10.5732\/cjc.009.10673","article-title":"Expression and clinical significance of androgen receptor in triple negative breast cancer","volume":"29","author":"Luo","year":"2010","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0715","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2025.156190_bb0720","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2025.156190_bb0725","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43951","article-title":"Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer","volume":"5","author":"Ryu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2025.156190_bb0730","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ajco.13478","article-title":"Tamoxifen use in recurrent ovarian cancer in a Chinese population: a 15 -year clinical experience in a tertiary referral center","volume":"17","author":"Chan","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.metabol.2025.156190_bb0735","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0959-8049(00)00228-8","article-title":"Tamoxifen in the treatment of recurrent ovarian carcinoma","volume":"36","author":"Trop\u00e9","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0740","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0370","article-title":"Aromatase inhibitors and newly developed nonalcoholic fatty liver disease in postmenopausal patients with early breast cancer: a propensity score-matched cohort study","volume":"24","author":"Lee","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.metabol.2025.156190_bb0745","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2017.05.002","article-title":"Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: a propensity score-matched cohort study","volume":"82","author":"Hong","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.metabol.2025.156190_bb0750","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/cas.12474","article-title":"A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer","volume":"105","author":"Lin","year":"2014","journal-title":"Cancer Sci"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T20:40:06Z","timestamp":1743972006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":150,"alternative-id":["S0026049525000599"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156190","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease: A sexually dimorphic disease and breast and gynecological cancer","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156190"}}